Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy for Very Low-Lying Clinical T3 Rectal Cancer: The NAIR Phase 2/3 Randomized Clinical Trial
Yuichiro Tsukada(National Cancer Center Hospital East), Masaaki Ito(National Cancer Centre Japan), Yuji Nishizawa(National Cancer Center Hospital East), Toshihiro Misumi(Yokohama City University), Keiji Koda(Teikyo University Chiba Medical Center), Fumihiko Fujita(Japan Society of Laparoscopic Colorectal Surgery), Hideaki Bando(Aichi Cancer Center), Takayuki Yoshino(University of Tsukuba), Koji Ikeda(Japan Society of Laparoscopic Colorectal Surgery), Akihiko Murata(Tottori University), Eiji Shinto(Self-Defense Forces Central Hospital), Riki Ohno(Saitama Cancer Center), Yoshikazu Koide(Fujita Health University Hospital), Norio Saitô(National Cancer Center Hospital East), Motoko Suzuki(St. Marianna University School of Medicine), Masayuki Ohue
Cited by 2
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k